Overdose Prevention Framework News Today

This announcement may be considered further progress in the implementation of the FDA Overdose Prevention Framework designed to prevent overdoses and reduce mortality.

The Food and Drug Administration (FDA) has issued draft guidance to facilitate the development of treatments for substance use disorders related to stimulants like cocaine and methamphetamine. The FDA’s draft guidance lays out the agency’s recommendations on the development of clinical trials for drugs aimed at treating moderate to severe cocaine use disorder, methamphetamine use…

/PRNewswire/ -- Today, the U.S. Food and Drug Administration published a new draft guidance to assist sponsors in developing treatments for stimulant use...

An update on activities FDA is taking across the agency in each of the Overdose Prevention Framework priorities.

The draft guidance, to help sponsors design clinical studies to evaluate these devices, furthers the FDA’s Overdose Prevention Framework goal of advancing evidence-based treatment for those with substance use disorders.

/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Thursday, the FDA issued an...

Buprenorphine is available either in a weekly injection formulation and a monthly formulation for patients already being treated with buprenorphine.

The FDA has approved extended-release injection buprenorphine (Brixadi, Braeburn Inc) for the treatment of moderate to severe opioid use disorder.

/PRNewswire/ -- Addressing the drug overdose crisis and substance use disorder (SUD) is an issue of great concern for our nation and remains a top public...

HHS also announces new actions to build on this progress Today, at the Whitman-Walker Health Center in Washington, D.C., U.S. Department of Health and Human